Compare BKV & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKV | IMNM |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | 452 | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | BKV | IMNM |
|---|---|---|
| Price | $30.19 | $23.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $34.22 | $32.80 |
| AVG Volume (30 Days) | 761.2K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | $69.39 | N/A |
| Revenue Next Year | $9.45 | $1,127.34 |
| P/E Ratio | $57.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.80 | $7.15 |
| 52 Week High | $32.81 | $27.65 |
| Indicator | BKV | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 63.22 | 57.72 |
| Support Level | $25.34 | $19.23 |
| Resistance Level | $30.31 | $25.10 |
| Average True Range (ATR) | 0.98 | 1.02 |
| MACD | 0.34 | 0.05 |
| Stochastic Oscillator | 96.90 | 63.51 |
BKV Corp is a growth-driven energy company focused on the development of natural gas-producing assets, the ownership and operation of natural gas-fired power generation assets, and selective accretive acquisitions. The company's core businesses are the production of natural gas and the generation of natural gas-fired power from its owned and operated assets, supported by a closed-loop plan, enabled by its upstream, midstream, power, and CCUS businesses.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.